Vestibular Schwannoma Clinical Trial
— SBNOfficial title:
Novel Multimodality Imaging Techniques for Neurosurgical Planning and Stereotactic Navigation in Lateral Skull Base Surgery: a Feasibility Study
NCT number | NCT04128345 |
Other study ID # | 17/0661 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | May 1, 2019 |
Est. completion date | May 2021 |
Successful neurosurgery to remove tumours around the base of the skull, such as a vestibular
schwannoma, depends on achieving maximal tumour removal whilst preserving crucial
neurological functions such as facial movement, and maintaining quality of life.
Current techniques to direct surgery are based on the surgeon's expertise and knowledge of
the relevant anatomy, supplemented by the use of electrical recording and stimulation of the
facial nerve. However, it is often very difficult to visualise the nerve during surgery and
facial nerve paralysis remains a potentially devastating complication of surgery.
Advanced imaging methods may be used to visualise important neural connections in the brain
and computer-assisted processing can generate tumour maps from MRI and ultrasound scans. This
study aims to utilise these technologies to develop a 3D navigation system for skull base
surgery.
This study aims to develop a system that will combine MRI and intraoperative ultrasound
imaging to enhance the surgeon's view of the tumour, facial nerve and other surrounding
critical structures during surgery. This information will be made available in the navigation
system in the operating room so that operations are more precise resulting in better tumour
removal rates and fewer complications.
The system will be assessed during the treatment of 20 patients with vestibular schwannoma at
the National Hospital for Neurology and Neurosurgery. This feasibility study will validate
the different parts of the new system and help us design a future research study to determine
its effectiveness in improving patient care.
This project will result in safer and more effective neurosurgery, with potential consequent
financial savings for the NHS and the UK, in addition to marked improvements in the quality
of life of patients and reduced dependency upon others.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | May 2021 |
Est. primary completion date | October 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Adult patients aged 18-85 years - Patients with a vestibular schwannoma who are scheduled for surgery - Patients willing and able to provide written informed consent Exclusion Criteria: - Patients aged under 18 years of age or older than 85 years - Previous, treated posterior fossa brain tumour(s) - Previous ear or facial surgery on ipsilateral side of tumour - Neurofibromatosis Type II - Participation in other clinical trials - Any contraindication for MR imaging - Any contraindication for MR contrast agent administration - Any contraindication for CT imaging - Pregnancy or breast feeding |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University College London/University College London Hospitals Joint Research Office | London |
Lead Sponsor | Collaborator |
---|---|
University College, London | University College London Hospitals NHS Foundation Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess the functionality and performance of a 3D surgical technical platform for integrating data from 3 different data sources (MRI, US and Neuronavigation data) in a clinical setting using a composite of quantitative and qualitative measurements | Composite of quantitative and qualitative measurements to assess the system's functionality and technical performance | Data will be collected on the date of patients' routine surgical procedure, assessed on 1 day from the start time (hh:hh) of set-up of the 3d surgical platform to the end time (hh:hh) of surgery | |
Secondary | Correlation of electromyographic stimulation of facial nerve with preoperatively acquired diffusion imaging | Stimulation response (binary outcome) and amplitude (mA) | A minimum of 9 time points (selected at random) during each surgical procedure, assessed on 1 day from the start time (hh:hh) to the end time (hh:hh) of surgery | |
Secondary | Postoperative tumour volume on contrast-enhanced MRI and its correlation with the final intraoperative ultrasound measurement | Tumour volume (cm3) on MRI and US | Final intraoperative US volume vs post op MRI volume (within 3 months) | |
Secondary | Average duration of surgical procedure using 3D navigation system | Time (hours) | From start time to end time of each surgical procedure, assessed on 1 day | |
Secondary | Documentation of technical system issues and implemented solutions | Documentation of technical system issues and implemented solutions (using qualitative research methods) | From start time to end time of each surgical procedure, assessed on 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Active, not recruiting |
NCT00973739 -
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
|
Phase 2 | |
Completed |
NCT04351373 -
Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560
|
Phase 2 | |
Active, not recruiting |
NCT01449604 -
Stereotactic Radiation in Vestibular Schwannoma
|
Phase 3 | |
Completed |
NCT01207687 -
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
|
Phase 2 | |
Not yet recruiting |
NCT05567341 -
Remote Ischemic Preconditioning in Vestibular Schwannoma Surgery
|
N/A | |
Completed |
NCT02249572 -
Vestibular Schwannoma - Radiosurgery or Expectation: V-REX.
|
N/A | |
Terminated |
NCT05116878 -
Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma
|
N/A | |
Suspended |
NCT03095248 -
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
|
Phase 2 | |
Recruiting |
NCT04801953 -
Nimodipine in Vestibular Schwanommas
|
Phase 2 | |
Recruiting |
NCT03745560 -
Intraoperative EABR for Decision Making
|
||
Recruiting |
NCT04859335 -
Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma
|
N/A | |
Active, not recruiting |
NCT01199978 -
Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma
|
Phase 2 | |
Recruiting |
NCT04057976 -
Use of DTT to Define Facial Nerve Position in Vestibular Schwannomas
|
N/A | |
Completed |
NCT00863122 -
Concentration and Activity of Lapatinib in Vestibular Schwannomas
|
Early Phase 1 | |
Recruiting |
NCT04374305 -
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
|
Phase 2 | |
Recruiting |
NCT03079999 -
Study of Aspirin in Patients With Vestibular Schwannoma
|
Phase 2 | |
Recruiting |
NCT05786144 -
Vestibular Schwannoma Organoids
|
||
Recruiting |
NCT03593577 -
Secondary Endolymphatic Hydrops and Vestibular Schwannomas on 3 Tesla MRI
|
||
Completed |
NCT03210285 -
WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data
|